Aims: To investigate sodium hyaluronate (SH) efficacy in the treatment of pregnancy rhinitis. Methods: A single-center, prospective, open-label, 2 parallel-group study was carried out. Pregnant women affected by pregnancy rhinitis were randomly assigned to 1 of 2 groups: Group A was treated with SH, while Group B did not receive any treatment. Pregnancy rhinitis symptoms and quality of life (QOL) during pregnancy were investigated by administering a questionnaire and carrying out an otorhinolaryngoiatric visit. Results: A significant reduction in the intensity of headache, snoring and insomnia in the Group A compared to the Group B were demonstrated. In the Group A, a significant lower presence of amount of secretions (Group A 0.88, 95% CI 0.57-1.18 vs. Group B 2.00, 95% CI 1.69-2.31, p < 0.001), turbinate hypertrophy (Group A 1.70, 95% CI 1.46-1.94 vs. Group B 2.53, 95% CI 2.29-2.77, p < 0.001), and mucosal congestion/hyperemia (Group A 1.41, 95% CI 1.14-1.68 vs. Group B 2.26, 95% CI 1.99-2.53, p < 0.001) was observed. No adverse events were reported in patients treated with SH. Conclusions: SH is a safe and effective therapeutic alternative for the treatment of pregnancy rhinitis symptoms, improving patients' QOL.

Effects of Sodium Hyaluronate on Symptoms and Quality of Life in Women Affected by Pregnancy Rhinitis: A Pilot Study

Favilli, Alessandro;Laurenti, Elena;STAGNI, GIAN MARIA;TASSI, LUIGI;Ricci, Giampietro;Gerli, Sandro
2019

Abstract

Aims: To investigate sodium hyaluronate (SH) efficacy in the treatment of pregnancy rhinitis. Methods: A single-center, prospective, open-label, 2 parallel-group study was carried out. Pregnant women affected by pregnancy rhinitis were randomly assigned to 1 of 2 groups: Group A was treated with SH, while Group B did not receive any treatment. Pregnancy rhinitis symptoms and quality of life (QOL) during pregnancy were investigated by administering a questionnaire and carrying out an otorhinolaryngoiatric visit. Results: A significant reduction in the intensity of headache, snoring and insomnia in the Group A compared to the Group B were demonstrated. In the Group A, a significant lower presence of amount of secretions (Group A 0.88, 95% CI 0.57-1.18 vs. Group B 2.00, 95% CI 1.69-2.31, p < 0.001), turbinate hypertrophy (Group A 1.70, 95% CI 1.46-1.94 vs. Group B 2.53, 95% CI 2.29-2.77, p < 0.001), and mucosal congestion/hyperemia (Group A 1.41, 95% CI 1.14-1.68 vs. Group B 2.26, 95% CI 1.99-2.53, p < 0.001) was observed. No adverse events were reported in patients treated with SH. Conclusions: SH is a safe and effective therapeutic alternative for the treatment of pregnancy rhinitis symptoms, improving patients' QOL.
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1445473
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact